Welcome to our dedicated page for Avalon Globocare SEC filings (Ticker: ALBT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Avalon GloboCare Corp. (NASDAQ: ALBT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8‑K and other key documents. These filings describe Avalon as a commercial‑stage company focused on precision diagnostic consumer products, cellular therapy intellectual property, generative AI publishing and software, and commercial real estate operations. Through its SEC reports, Avalon details material events such as acquisitions, financing arrangements, Nasdaq listing matters, and progress on its proposed merger with YOOV Group Holding Limited.
In recent Form 8‑K filings, Avalon has reported the acquisition of RPM Interactive, Inc. through its subsidiary Avalon Quantum AI, LLC, adding a generative AI powered SaaS platform for automated short‑form video creation. Other 8‑K and 8‑K/A filings outline senior secured promissory notes, bridge notes, waivers and amendments, unregistered sales of equity securities, and changes to preferred stock designations, including Series C and Series E preferred stock. Filings also document Nasdaq correspondence regarding compliance with the minimum stockholders’ equity requirement under Listing Rule 5550(b) and the company’s steps to address those requirements.
SEC filings further describe Avalon’s Agreement and Plan of Merger with YOOV Group Holding Limited and the related Registration Statement on Form S‑4, which contains a preliminary proxy statement/prospectus. These documents explain the structure of the proposed merger, the conditions to closing, and the anticipated focus on Artificial Intelligence‑as‑a‑Service (AIaaS) solutions following completion. Additional disclosures cover the company’s share issuances, beneficial ownership limitations, and updates on outstanding notes and conversion terms.
On Stock Titan, users can review Avalon’s 8‑K, 8‑K/A, 10‑K, and other SEC filings, while AI‑powered tools help summarize complex sections, highlight key terms, and surface information on topics such as financing, preferred stock features, Nasdaq listing status, and merger‑related disclosures. This makes it easier to understand how Avalon’s precision diagnostics, cellular therapy IP, AI software assets, and capital structure are reflected in its official regulatory record.
Avalon GloboCare Corp. terminated its planned merger with YOOV Group Holding Limited. On January 21, 2026, Avalon, its Nexus MergerSub subsidiary, and YOOV signed a Mutual Termination and Release Agreement that ends the March 7, 2025 Merger Agreement, with only specified surviving provisions remaining.
The parties agreed that no termination fee, expense reimbursement, or other payment is owed by either side, and each granted the other a broad mutual release of claims related to the proposed merger, subject to exceptions for rights under the termination deal, certain surviving provisions, and claims based on fraud or intentional misrepresentation. They also agreed to a mutual non‑disparagement covenant lasting three years and reciprocal indemnification for breaches, capped at $500,000 per side, excluding fraud or intentional misrepresentation.
Separately, Avalon disclosed that its subsidiary Avalon Quantum AI LLC filed a U.S. provisional patent application covering systems and methods for evidence‑constrained, audience‑adaptive automated commentary videos.
Avalon Globocare Corp. filed a current report to share that it issued a press release providing updates on its KetoAir™ breathalyzer device. The filing states that the press release, attached as an exhibit, is being furnished under Regulation FD, which is used to distribute important company information broadly and at the same time to all investors. The company also clarifies that this information is not considered “filed” for liability purposes under securities laws unless specifically incorporated into another filing.
Avalon GloboCare Corp. announced that Nasdaq has notified the company it has regained compliance with the Nasdaq Capital Market’s minimum stockholders’ equity requirement under Listing Rule 5550(b). Nasdaq also confirmed that the company is now in compliance with all applicable continued listing standards, meaning its common stock will continue to trade on the Nasdaq Capital Market. A previously scheduled hearing before the Nasdaq Hearings Panel has been cancelled, and the company issued a press release describing these developments.
Avalon GloboCare Corp. completed a business combination with RPM Interactive, Inc., issuing 19,500 shares of Series E Non-Voting Convertible Preferred Stock with an aggregate stated and liquidation value of $19,500,000.00 to RPM stockholders. Each Series E share has a stated value of $1,000, ranks senior to common stock, and is convertible into common stock at $1.50 per share from May 12, 2026, subject to ownership limits, an exchange cap under Nasdaq rules and stockholder approval. As a result of this transaction, Avalon believes its stockholders’ equity now exceeds the $2.5 million level required for continued Nasdaq listing.
The company also issued a $375,000 unsecured bridge note with a $75,000 original issue discount, receiving $300,000 in cash and agreeing to issue 100,000 commitment shares, with the note convertible on default into common stock at 50% of the volume weighted average price over the five prior trading days, subject to a floor price and prior shareholder approval. Avalon plans to issue 305,000 restricted shares to consultants, after which 4,557,009 common shares will be outstanding. In connection with the merger, Michael Mathews was appointed to the board as a director.
Avalon GloboCare Corp. reported that Nasdaq has again found it out of compliance with the Nasdaq Capital Market’s continued listing standards due to low stockholders’ equity and related criteria. Nasdaq previously notified the company that its stockholders’ equity was a deficit of
Nasdaq had granted Avalon GloboCare up to 180 days from May 22, 2025, through November 18, 2025, to regain compliance. On November 19, 2025, Nasdaq sent a new notice stating the company remains non‑compliant and that its common stock is subject to suspension and delisting unless it requests a hearing. Avalon GloboCare plans to request a hearing before a Nasdaq Hearings Panel, which will automatically stay any suspension or delisting while the hearing process and any Panel‑granted extension period are ongoing.
Avalon GloboCare Corp. filed a current report to share that it has updated its investor presentation, which may be used in meetings with investors and analysts. The presentation includes additional information about YOOV Group Holding Limited and certain preliminary financial data for YOOV in connection with their previously announced proposed merger, under which YOOV would become a wholly owned direct subsidiary of Avalon GloboCare.
The filing stresses that YOOV’s preliminary figures are prepared by YOOV management, have not been audited or reviewed by its independent public accounting firm, and may change when YOOV’s audited results for the year ended March 31, 2025 are finalized. The report also highlights that the merger remains subject to conditions such as stockholder approval and other closing requirements, points investors to the Form S-4 registration statement and proxy statement/prospectus filed with the SEC for detailed information, and includes extensive forward-looking statement and risk disclosures related to the proposed merger.
Avalon GloboCare Corp. filed an amended current report to clarify details of a financing agreement, a senior secured promissory note, and related preferred stock terms.
The company agreed to sell 141,643 shares of common stock for $500,000, or $3.53 per share, to York Sun Investment Holding Limited under a securities purchase agreement. It also entered into a waiver with Mast Hill Fund, L.P. under a $2,845,000 senior secured promissory note, under which the holder waived potential cash penalties tied to a prior issuance of Series C preferred stock but retained dilutive adjustment rights, subject to a $1.00 per-share floor price.
Based on principal, accrued, and estimated future interest, the report states that, at the floor price, the note could be converted into approximately 2,942,041 common shares, subject to a 4.99% beneficial ownership limit. Separately, the Series C preferred stock designation was amended to reduce its beneficial ownership limit from 19.99% to 4.99%, further constraining how much any holder can own through conversion.
Avalon GloboCare Corp. filed a current report describing a planned product launch. The company announced that it intends to begin selling its KetoAir™ breathalyzer device in the United Kingdom starting on September 1, 2025. This step represents an international rollout of the KetoAir™ product beyond existing markets. The announcement was made through a press release that is included as an exhibit and is referenced for further details on the planned UK introduction.
Avalon GloboCare Corp. (ALBT) reported continued operating losses and significant balance sheet activity in the six months ended June 30, 2025. The company recorded recurring net losses of approximately $15.94 million for the six-month period and generated negative operating cash flow of about $3.03 million. During Q1 2025 Avalon completed the redemption of its 40% equity interest in Lab Services MSO for aggregate cash of $1.745 million and the surrender of Series B preferred stock (carrying value $11.0 million), recognizing an increase to additional paid-in capital of $2.3487 million. The company recorded a $9.0766 million loss on extinguishment of debt related to modification/waiver of the June 2024 convertible note financing. Derivative liabilities declined, producing a fair value gain of $446,816 for the six months. The company wrote off and reserved for credit losses ($1.65 million) and reported material warrant and convertible instruments, including the June 2024 convertible note (principal $2.845 million). Avalon’s laboratory services segment ceased upon the Lab Services MSO redemption; the real property segment remains operational.
Avalon GloboCare Corp. issued 221,000 shares of unregistered common stock to a noteholder upon partial conversions of an outstanding promissory note between July 30, 2025 and August 6, 2025. After these issuances the company reported 3,690,109 shares outstanding as of August 6, 2025. The filing states the shares were not registered under the Securities Act and were offered in reliance on the Section 4(a)(2) exemption.
The disclosure provides the exact share amount and updated share count but contains no details on the promissory note balance converted, the conversion price, or any cash impacts. The information is factual and narrow in scope, limited to the share issuance and the registration exemption relied upon.
FAQ
What is the current stock price of Avalon Globocare (ALBT)?
What is the market cap of Avalon Globocare (ALBT)?
